Literature DB >> 21745436

The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects.

Pradeep J Nathan1, Barry V O'Neill, Karin Mogg, Brendan P Bradley, John Beaver, Massimo Bani, Emilio Merlo-Pich, Paul C Fletcher, Bridget Swirski, Annelize Koch, Chris M Dodds, Edward T Bullmore.   

Abstract

The mesolimbic dopamine system plays a critical role in the reinforcing effects of rewards. Evidence from pre-clinical studies suggests that D₃ receptor antagonists may attenuate the motivational impact of rewarding cues. In this study we examined the acute effects of the D₃ receptor antagonist GSK598809 on attentional bias to rewarding food cues in overweight to obese individuals (n=26, BMI mean=32.7±3.7, range 27-40 kg/m²) who reported binge and emotional eating. We also determined whether individual differences in restrained eating style modulated the effects of GSK598809 on attentional bias. The study utilized a randomized, double-blind, placebo-controlled cross-over design with each participant tested following acute administration of placebo and GSK598809 (175 mg). Attentional bias was assessed by the visual probe task and modified Stroop task using food-related words. Overall GSK598809 had no effects on attentional bias in either the visual probe or food Stroop tasks. However, the effect of GSK598809 on both visual probe and food Stroop attentional bias scores was inversely correlated with a measure of eating restraint allowing the identification of two subpopulations, low- and high-restrained eaters. Low-restrained eaters had a significant attentional bias towards food cues in both tasks under placebo, and this was attenuated by GSK598809. In contrast, high-restrained eaters showed no attentional bias to food cues following either placebo or GSK598809. These findings suggest that excessive attentional bias to food cues generated by individual differences in eating traits can be modulated by D₃ receptor antagonists, warranting further investigation with measures of eating behaviour and weight loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745436     DOI: 10.1017/S1461145711001052

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  24 in total

1.  Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Authors:  Samuel R Chamberlain; Karin Mogg; Brendan P Bradley; Annelize Koch; Chris M Dodds; Wenli X Tao; Kay Maltby; Bhopinder Sarai; Antonella Napolitano; Duncan B Richards; Edward T Bullmore; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

2.  Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Authors:  Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-07       Impact factor: 7.853

3.  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Authors:  Anne Stößel; Regine Brox; Nirupam Purkayastha; Harald Hübner; Carsten Hocke; Olaf Prante; Peter Gmeiner
Journal:  Bioorg Med Chem       Date:  2017-04-29       Impact factor: 3.641

4.  A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.

Authors:  Sarah A Eisenstein; Jo Ann V Antenor-Dorsey; Danuta M Gredysa; Jonathan M Koller; Emily C Bihun; Samantha A Ranck; Ana Maria Arbeláez; Samuel Klein; Joel S Perlmutter; Stephen M Moerlein; Kevin J Black; Tamara Hershey
Journal:  Synapse       Date:  2013-05-30       Impact factor: 2.562

5.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

Review 6.  Selectivity of probes for PET imaging of dopamine D3 receptors.

Authors:  Robert K Doot; Jacob G Dubroff; Kyle J Labban; Robert H Mach
Journal:  Neurosci Lett       Date:  2018-03-05       Impact factor: 3.046

7.  Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans.

Authors:  Patricia Di Ciano; Esmaeil Mansouri; Junchao Tong; Alan A Wilson; Sylvain Houle; Isabelle Boileau; Thierry Duvauchelle; Philippe Robert; Jean Charles Schwartz; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2018-11-30       Impact factor: 7.853

8.  Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.

Authors:  V Román; I Gyertyán; K Sághy; B Kiss; Zs Szombathelyi
Journal:  Psychopharmacology (Berl)       Date:  2012-11-09       Impact factor: 4.530

9.  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.

Authors:  Thomas M Keck; William S John; Paul W Czoty; Michael A Nader; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-03-31       Impact factor: 7.446

10.  Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

Authors:  Pierre Sokoloff; Ludovic Leriche; Jorge Diaz; Jacques Louvel; René Pumain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.